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Abstract: Diabetic kidney disease leads to microalbuminuria and
gradually progresses to overt proteinuria with renal insufficiency.
Recent studies have demonstrated that 20% to 40% of patients with
diabetic kidney disease are normo- to microalbuminuric, despite
reduced renal function. We investigated renal and cardiovascular out-
comes in patients with diabetes and renal insufficiency who were
normo-, micro-, and macroalbuminuric.
Patients with diabetes and stage III or IV chronic kidney disease
were recruited and divided into normoalbuminuric, microalbuminuric,
and macroalbuminuric groups. New-onset cardiovascular events and
renal outcomes, defined by end-stage renal disease or a 50% decline in
estimated glomerular filtration rate, were evaluated.
Among the 1136 study patients, 255 (22.4%) were normoalbumi-
nuric. During a mean follow-up duration of 44 months, the incidence of
cardiovascular disease was similar among groups (P¼ 0.68). However,
renal outcomes were significantly more common in patients with
macroalbuminuria than in those who were normoalbuminuric or micro-
albuminuric (P< 0.001). Multivariate Cox analysis identified macro-
albuminuria and estimated glomerular filtration rate as independent
predictors of renal outcomes. The amount of albuminuria was not
associated with cardiovascular events in this population.
Although cardiovascular events were similar in patients with dia-
betic kidney disease and renal insufficiency, renal outcomes differed
significantly according to the amount of albuminuria.
(Medicine 95(15):e3175)Park, MD, PhD, an, MD, PhD,
, MD, PhD, and Tae-Hyun Yoo, MD, PhD
disease, eGFR = estimated glomerular filtration rate, ESRD = end-
stage renal disease, HbA1c = hemoglobin A1c, IRB = Institutional
Review Board.
INTRODUCTION
T he prevalence of diabetes mellitus has increased as a resultof extended average life expectancy and an increasing rate
of obesity. As the rate of diabetes has risen, diabetic kidney
disease (DKD), a chronic microvascular complication, has also
become more prevalent. DKD is characterized by albuminuria
and reduced renal function, and is the leading cause of end-stage
renal disease (ESRD), accounting for 42% of ESRD patients
starting renal replacement therapy.1 Atherosclerotic cardiovas-
cular disease (CVD) is also highly prevalent in patients with
diabetes, especially in patients with reduced renal function.
Moreover, DKD is significantly associated with high mortality
and morbidity caused by CVD.2,3 Although the histologic
findings and pathophysiologic mechanisms of DKD are rela-
tively similar in patients with type 1 and 2 diabetes mellitus,
certain differences exist in the natural course of DKD pro-
gression. Patients with type 1 diabetes develop microalbumi-
nuria approximately 10 to 15 years after the onset of diabetes,
and this condition subsequently progresses to overt proteinuria,
consequent hypertension, and renal insufficiency.4 In patients
with type 2 diabetes, more heterogeneous clinical presentations,
including albuminuria, hypertension, and reduced renal func-
tion, are demonstrated, even at the onset of diabetes mellitus.5
Albuminuria, including microalbuminuria, is one of the earliest
clinical signs of DKD and is a marker of renal progression and
an increased risk of cardiovascular morbidity.6 Since early and
aggressive treatment of albuminuria can alleviate or delay DKD
progression,7 appropriate screening at an early stage is manda-
tory in these patients. According to a United Kingdom Pro-
spective Diabetes Study report, patients with DKD and
macroalbuminuria progress to renal failure, although a sub-
stantial number of patients with diabetes without albuminuria
and those with microalbuminuria also show renal dysfunction.8
MacIsaac et al9 also reported that 39% of diabetic patients with
advanced (over stage 3) chronic kidney disease (CKD) had
urine albumin levels in the normal range. In the DEMAND
study, a recent cross-sectional study, patients with normoalbu-
minuria and advanced renal insufficiency accounted for 20% of
the total, and these patients also had a high risk of CVD.10 In
Asian populations, patients with diabetes without albuminuria
often show a decline in renal function, and the incidence of
CVD is relatively similar between patients with macroalbumi-
nuria and normoalbuminuria.11 These findings suggest thaton per se is an independent prognostic
ar outcome in patients with diabetes,
unt of albuminuria. The Kidney Disease
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Outcomes Quality Initiative (KDOQI) guidelines recommend
that patients with diabetes should be screened by simul-
taneously measuring the urinary albumin-to-creatinine ratio
(ACR) and estimated glomerular filtration rate (eGFR).12
The KDOQI also mentioned special circumstances in which
to suspect nondiabetic renal disease, such as in patients with
diabetes and a low eGFR who do not have microalbuminuria or
macroalbuminuria or other microvascular complications,
including diabetic retinopathy. Based on previous studies, renal
insufficiency accompanied by normoalbuminuria is relatively
common in patients with diabetes but may reflect disease
progression in terms of renal or cardiovascular outcome. How-
ever, few studies have investigated the long-term prognosis of
these patients while focusing on renal and cardiovascular out-
comes. The present study aimed to ascertain these clinical
differences by comparing both the development of cardiovas-
cular complications and the progression to ESRD or a 50%
decline in eGFR in patients with diabetes and renal insuffi-
ciency according to the amount of albuminuria.
METHODS
Study Population
Between January 2007 and December 2009, 14,245
patients with type 2 diabetes mellitus visited our outpatient
clinics. Demographic and laboratory data were retrospectively
retrieved from the Yonsei Electronic Medical Record Database.
The eGFRwas calculated from serum creatinine levels using the
Chronic Kidney Disease Epidemiology Collaboration
equation.13 Patients with type 2 diabetes and impaired renal
function (eGFR< 60mL/min/1.73m2) were included in this
analysis. The amount of albuminuria was assessed by spot urine
ACR. Study subjects were divided according to the amount of
albuminuria into normoalbuminuria (ACR< 30mg/g), micro-
albuminuria (ACR 30–300mg/g), and macroalbuminuria
(ACR> 300mg/g) groups. Criteria for exclusion were extre-
mely young or old age (<18 years or >75 years), acute kidney
injury, and preserved renal function (eGFR> 60mL/min/
1.73m2). Patients with stage 5 CKD or patients on dialysis
therapy were also excluded. We also excluded patients for
whom ACRs were not available and those with a relatively
short follow-up duration (<6 months). This study was carried
out in accordance with the Declaration of Helsinki and approved
by the Institutional Review Board (IRB) of Yonsei University
Health System Clinical Trial Center. Since this was a retro-
spective study and subjects were deidentified, the IRB waived
the need to obtain written informed consent from the study
subjects.
Data Collection
Demographic and clinical data collected at the time of
study enrollment included age, sex, systolic and diastolic blood
pressure, history of CVD, and laboratory parameters, including
blood urea nitrogen (BUN), creatinine, and lipid profiles includ-
ing total cholesterol, triglyceride, HDL, and LDL cholesterol
levels, and spot urine ACR.
Study Endpoints
The cardiovascular composite endpoint was any major
cardiovascular and cerebrovascular event. A major cardiovas-
Lee et alcular event was defined as cardiovascular mortality and hospi-
talization for acute coronary syndrome or coronary
revascularization, including percutaneous coronary intervention
2 | www.md-journal.comor coronary artery bypass graft. Acute coronary syndrome was
defined as presentation with chest pain and/or ischemic elec-
trocardiographic changes and elevation of troponin T, with
evidence of infarct by stress imaging or coronary angiography
and ventriculography. Cerebrovascular events included both
nonfatal ischemic stroke and nonfatal hemorrhagic stroke.
Renal outcome was defined as a 50% decline in eGFR or
development of ESRD, which was defined as initiation of renal
replacement therapy, including hemodialysis, peritoneal dialy-
sis, or kidney transplantation. In subgroup analysis, we defined
good glycemic control group as hemoglobin A1c (HbA1c)
below 8% and poor glycemic control group as HbA1c above
8%.14 All events were retrieved from the database and carefully
reviewed to determine the incidence of cardiovascular outcomes
or renal outcomes.
Statistical Analysis
All variables are expressed as the mean standard devi-
ation or percentage. Normality of the distribution of variables
was tested by the Kolmogorov–Smirnov test. Comparisons
were evaluated by Chi-square test, Student t test, or analysis
of variance (ANOVA). Survival curves were created using the
Kaplan–Meier method, and comparisons were made using the
log-rank test. A Cox proportional hazards model was used to
identify independent variables affecting event-free survival, and
the results are presented as hazard ratio (HR) and 95% confi-
dence interval (CI). Possible bias from different baseline
characteristics among the 3 groups was calibrated by propensity
score matching using logistic regression with the independent
variables including age, duration of diabetes, eGFR, and any
underlying CVD. Propensity score matching was conducted
with greedy nearest neighbor matching using SAS version 9.1
(SAS Institute, Cary, NC).15 After all propensity score matches
were performed, we assessed the balance in baseline covariates
among the three groups using the ANOVA test for continuous
variables and the Chi-square test for categorical variables.
Results of time-dependent covariate analysis, which was used
to confirm the assumption of proportionality, were not statisti-
cally significant, suggesting that the proportional hazards
assumption is reasonable. All tests were 2 sided, and
Medicine  Volume 95, Number 15, April 2016P< 0.05 was considered significant. Statistical analyses were
performed with SPSS for Windows, version 18.0 (SPSS, Inc.,
Chicago, IL).
RESULTS
Baseline Patient Characteristics According to the
Amount of Albuminuria
Among the 14,245 patients with type 2 diabetes initially
screened, 1564 had decreased renal function (eGFR< 60mL/
min/1.73m2). After 428 patients were excluded, the final
analysis included 1136 patients who were then classified into
3 groups according to the amount of albuminuria: a normoal-
buminuria group (255 patients, 22.4%), a microalbuminuria
group (275 patients, 24.2%), and a macroalbuminuria group
(606 patients, 53.3%) (Figure 1). The mean age was 61.7 years,
and 391 patients (34.4%) were women. The mean eGFR was
38.9 13.9mL/min/1.73m2. The mean age and eGFR were
significantly lower in the macroalbuminuria group, whereas
creatinine and HbA1c levels were significantly higher in the
macroalbuminuria group than in the normoalbuminuria and
microalbuminuria groups. Patients in the macroalbuminuria
group had a longer duration of diabetes, whereas a history of
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
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the normoalbuminuria or microalbuminuria groups. No signifi-
cant differences in sex, body mass index (BMI), hypertension or
lipid profiles were found among the 3 groups (Table 1).
Cardiovascular and Renal Outcomes
During a mean follow-up duration of 44 months, new-
onset cardiovascular events developed in 191 patients (16.8%).
FIGURE 1. Flow chart of the study population. Patients with dia
screened for enrollment. A total of 1136 patients with diabetes aThese events included 127 cardiovascular events and 50
cerebrovascular events. There were 14 patients who had both
cardiovascular and cerebrovascular events. The incidence of
TABLE 1. Baseline Characteristics of Study Subjects According to
Variables NA (n¼ 255)
Age, y 64.92 8.33
Sex, n, % female 70 (44.3%)
BMI, kg/m2 24.76 3.21
Hypertension, n, % 197 (77.25%)
History of CVD, n, % 90 (35.3%)
Duration of DM, y 9.86 8.4
Serum creatinine 1.53 0.37
eGFR, mL/min/1.73m2 45.3 11.8
ACR, mg/g 17.4 7.8
Total cholesterol, mg/dL 171 43.1
Triglyceride, mg/dL 180.25 121.04
HDL, mg/dL 42.28 10.58
LDL, mg/dL 102.11 34.55
Hemoglobin A1c, %, mmol/mol 7.5 1.5, 58 16.4

<0.01, among 3 groups.
<0.05, among 3 groups.
y<0.05, NA vs MiA group.
Data are expressed as mean standard deviation, or number of patients
CVD¼ cardiovascular disease, DM¼ diabetes mellitus, eGFR¼ estimated
lipoprotein cholesterol, LDL¼ low-density lipoprotein cholesterol, MA¼m
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.cardiovascular events was 3.90 per 1000 person-years in the
normoalbuminuria group, 4.21 per 1000 person-years in the
microalbuminuria group, and 4.10 per 1000 person-years in
the macroalbuminuria group. Cardiovascular outcomes were
comparable among the three groups. However, renal outcomes,
defined by progression to ESRD or a 50% decline in eGFR,
were significantly higher in the macroalbuminuria group than in
the normoalbuminuria and microalbuminuria groups (9.88,
es who visited our clinic between 2007 and 2009 were initially
stage III or IV chronic kidney disease (CKD) were analyzed.0.63, and 0.95 per 1000 person-years in the macroalbuminuria,
normoalbuminuria, and microalbuminuria groups, respectively;
P< 0.01; Table 2).
the Amount of Albuminuria
MiA (n¼ 275) MA (n¼ 606) P
64.20 10.41 59.27 11.38 <0.01
69 (34.5%) 124 (30%) 0.54
25.37 13.75 24.43 4.87 0.26
205 (74.5%) 457 (75.4%) 0.35
88 (32%) 167 (27.6%)

0.02
10.94 8.53 12.98 8.94 <0.01
1.78 0.52y 2.08 0.79 <0.01
39.6 12.9y 36.1 14.4 <0.01
85.1 55.9 1625.8 1844.7 <0.01
165.6 40.1 177.1 61.9 0.01
173.8 123.43 179 126.57 0.74
42.05 11.32 43.57 15.33 0.98
102.2 32.84 106.56 42.12 0.43
7.6 1.6, 60 17.5 7.9 1.8, 63 19.7 <0.01
(percent).ACR¼ albumin-to-creatinine ratio, BMI¼ body mass index,
glomerular filtration rate by CKD-EPI equation, HDL¼ high-density
acroalbuminuria, MiA¼microalbuminuria, NA¼ normoalbuminuria.
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TABLE 2. Incidence of Cardiovascular Events and Renal Outcomes According to the Amount of Albuminuria
NA Group (n¼ 255) MiA Group (n¼ 275) MA Group (n¼ 606)
N (%) /1000 P-Y N (%) /1000 P-Y N (%) /1000 P-Y
Cardiovascular outcomes 41 (16.1%) 3.90 51 (18.5%) 4.21 99 (16.3%) 4.10
Cardiovascular events 30 (11.8%) 29 (10.5%) 68 (11.2%)
Cerebrovascular events 8 (3.1%) 17 (6.2%) 25 (4.1%)
Both events 3 (1.2%) 5 (1.8%) 6 (1.0%)
Renal outcomes 7 (2.7%) 0.63 12 (4.4%) 0.95 260 (42.9%) 9.88
Data are expressed as number of patients (percent).
MA¼macroalbuminuria, MiA¼microalbuminuria, NA¼ normoalbumin
Lee et al Medicine  Volume 95, Number 15, April 2016
4 | www.md-journal.comKaplan–Meier plots revealed no significant differences in
new-onset cardiovascular events among the three groups
(P¼ 0.68; Figure 2A). However, in terms of renal outcomes,
patients in the macroalbuminuria group had a significantly
higher risk of a 50% decline of eGFR or ESRD compared with
those in the normoalbuminuria and microalbuminuria groups
(P< 0.001; Figure 2B). We performed a Cox proportional
hazard analysis to identify independently associated factors.
The amount of albuminuria in study subjects was not a signifi-
cant risk factor for cardiovascular events (HR, 1.138; 95% CI:
0.941–1.376; P¼ 0.18) in the study population. CVD history
and hypertension, however, were independent risk factors for
new-onset cardiovascular events (HR, 1.947; 95% CI: 1.441–
2.631; P< 0.01 and HR, 1.384; 95%CI: 1.010–1.967; P¼ 0.04,
respectively; Table 3). Meanwhile, after adjusting for con-
founding variables, the amount of albuminuria (HR: 2.472,
95% CI: 1.988–3.075, P< 0.01) and eGFR (HR: 0.970, 95%
CI: 0.959–0.981, P< 0.01) were independent risk factors for
renal outcomes.
In addition, subgroup analysis was conducted in good and
poor glycemic control group. CVD history was an independent
risk factor of cardiovascular outcomes in both subgroups. For
renal outcomes, the amount of albuminuria and eGFR were
independent risk factor in both subgroups (Table 4). Kaplan–
Meier survival analysis also showed same trends among the 3
groups according to level of albuminuria even in subgroup
according to good or poor glycemic control (Figure 3).
Propensity Score Matching Analysis
To adjust for differences in baseline characteristics, we
performed propensity score matching using four variables (age,
eGFR, duration of diabetes, and history of CVD), selecting 145
patients in each group (Table 5). Kaplan–Meier plots also
showed that cardiovascular outcome did not differ among the
uria, P-Y¼ person-years.normoalbuminuria, microalbuminuria, and macroalbuminuria
groups (P¼ 0.73; Figure 4A), although patients in the macro-
albuminuria group still had a significantly higher risk of renal
FIGURE 2. Kaplan–Meier plots for cardiovascular outcomes (A)
and renal outcomes (B) according to the amount of albuminuria.
New-onset cardiovascular events are comparable among the three
groups (P¼0.68). However, macroalbuminuric patients have a
significantly higher risk of renal outcomes (defined by a 50%
decline in eGFR or ESRD) compared with patients with normoal-
buminuria and microalbuminuria (P<0.001).
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Multivariate Cox Proportional Hazard Analysis for Cardiovascular and Renal Outcomes
Cardiovascular Outcomes Renal Outcomes
HR 95% CI P HR 95% CI P
DM duration, y 1.001 0.984–1.018 0.92 1.025 1.010–1.039 <0.01
Age, y 1.002 0.988–1.017 0.75 0.989 0.976–1.003 0.12
Sex (vs female) 0.760 0.543–1.063 0.11 0.716 0.530–0.967 0.03
BMI, kg/m2 1.006 0.995–1.016 0.31 0.974 0.942–1.006 0.11
Hypertension 1.384 1.010–1.967 0.04 1.450 1.039–2.025 0.03
CVD history 1.947 1.441–2.631 <0.01 0.839 0.615–1.146 0.27
logACR, mg/g 1.138 0.941–1.376 0.18 2.472 1.988–3.075 <0.01
eGFR, mL/min/1.73m2 0.997 0.986–1.008 0.60 0.970 0.959–0.981 <0.01
Triglyceride, mg/dL 0.999 0.998–1.001 0.37 0.999 0.998–1.000 0.15
HDL, mg/dL 0.996 0.984–1.008 0.53 0.995 0.985–1.004 0.28
LDL, mg/dL 0.997 0.993–1.001 0.16 0.995 0.992–0.999 0.01
HbA1c, % 0.952 0.869–1.043 0.29 1.003 0.930–1.081 0.95
ACR¼ albumin-to-creatinine ratio, BMI¼ body mass index, CI¼ confidence interval, CVD¼ cardiovascular disease, DM¼ diabetes mellitus,
eGFR¼ estimated glomerular filtration rate by CKD-EPI equation, HbA1c¼ hemoglobin A1c, HDL¼ high-density lipoprotein cholesterol,
Medicine  Volume 95, Number 15, April 2016 Cardiovascular Events in Normoalbuminuric Diabetic Patientsprogression than patients in the normoalbuminuric or micro-
albuminuric groups (P< 0.001; Figure 4B).
DISCUSSION AND CONCLUSIONS
This study was performed to investigate the clinical
characteristics of patients with diabetes and decreased renal
function by comparing cardiovascular and renal outcomes
according to the amount of albuminuria. We demonstrated that
HR¼ hazard ratio, LDL¼ low-density lipoprotein cholesterol.cardiovascular outcomes were comparable among the normoal-
buminuric, microalbuminuric, and macroalbuminuric groups of
patients with DKD and reduced renal function. Meanwhile, the
TABLE 4. Multivariate Cox Proportional Hazard Analysis for Cardio
Good Glycemic Control (HbA1c 8%, n¼
Cardiovascular
Outcomes
Renal
Outcome
HR 95% CI P HR 95% CI
DM duration, y 0.990 0.979–1.019 0.93 1.017 0.996–1.03
Age, y 1.009 0.991–1.027 0.32 0.995 0.978–1.01
Sex (vs female) 0.679 0.450–1.023 0.06 0.659 0.441–0.98
BMI, kg/m2 1.006 0.995–1.017 0.27 0.981 0.946–1.01
Hypertension 1.390 0.892–2.166 0.15 1.380 0.893–2.13
CVD history 2.003 1.395–2.877 <0.01 0.750 0.501–1.12
logACR, mg/g 1.078 0.857–1.354 0.52 2.597 1.960–3.44
eGFR, mL/min/1.73m2 0.996 0.983–1.010 0.60 0.975 0.961–0.98
Triglyceride, mg/dL 0.999 0.998–1.001 0.25 0.999 0.998–1.00
HDL, mg/dL 0.990 0.974–1.006 0.21 0.989 0.975–1.00
LDL, mg/dL 0.996 0.990–1.002 0.19 0.995 0.990–1.00
HbA1c, % 1.033 0.795–1.342 0.81 0.926 0.743–1.15
ACR¼ albumin-to-creatinine ratio, BMI¼ body mass index, CI¼ confid
eGFR¼ estimated glomerular filtration rate by CKD-EPI equation, Hb
HR¼ hazard ratio, LDL¼ low-density lipoprotein cholesterol.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.amount of albuminuria was closely related to renal outcomes in
patients with DKD and renal insufficiency, as previously
reported.16
Chronic diabetic complications are classified as micro-
vascular or macrovascular according to the size of the affected
vessel and affected organs. Diabetic nephropathy, as a repre-
sentative microvascular complication of diabetes, is character-
ized by albuminuria and subsequent renal dysfunction.17Albuminuria is a distinctive sign of diabetic nephropathy and
is also closely associated with the development of cardiovas-
cular events.18,19 Macrovascular complications are defined as
vascular and Renal Outcomes According to Glycemic Control
735) Poor Glycemic Control (HbA1c> 8%, n¼ 401)
s
Cardiovascular
Outcomes
Renal
Outcomes
P HR 95% CI P HR 95% CI P
9 0.12 1.007 0.974–1.042 0.66 1.054 1.025–1.083 <0.01
3 0.58 0.988 0.960–1.016 0.39 0.979 0.957–1.002 0.08
6 0.04 0.986 0.537–1.813 0.97 0.829 0.509–1.35 0.45
6 0.28 0.985 0.931–1.041 0.59 0.960 0.901–1.022 0.20
3 0.15 1.441 0.721–2.881 0.30 1.324 0.758–2.312 0.32
4 0.16 1.918 1.081–3.401 0.03 1.256 0.746–2.116 0.39
1 <0.01 1.254 0.864–1.821 0.23 2.614 1.754–3.896 <0.01
9 <0.01 1.000 0.980–1.02 1 0.962 0.945–0.980 <0.01
1 0.47 1.000 0.998–1.003 0.74 0.998 0.995–1.000 0.05
3 0.11 1.007 0.988–1.027 0.49 1.000 0.987–1.014 0.95
0 0.06 0.999 0.991–1.006 0.76 0.995 0.989–1.001 0.09
5 0.50 1.033 0.857–1.245 0.74 1.067 0.919–1.239 0.39
ence interval, CVD¼ cardiovascular disease, DM¼ diabetes mellitus,
A1c¼ hemoglobin A1c, HDL¼ high-density lipoprotein cholesterol,
www.md-journal.com | 5
FIGURE 3. Kaplan–Meier plots for cardiovascular outcomes (A) and renal outcomes (B) according to the amount of albuminuria in
patients with good glycemic control (8%) and cardiovascular outcomes (C) and renal outcomes (D) according to the amount of
albuminuria in patients with poor glycemic control (>8%). Cardiovascular outcomes are not different among the three groups in both
gro
d m
Lee et al Medicine  Volume 95, Number 15, April 2016premature accelerated atherosclerosis in medium to large
vessels, and its related signs and symptoms vary depending
on the affected artery or organ.20,21 eGFR reflects renal function
and is influenced by the number of functional nephrons or the
amount of renal blood flow. Glomerular diseases, including
DKD, are associated with albuminuria, consequent capillary
damage, and glomerulosclerosis.22 Diabetic glomerulosclerosis
is associated with a decreased surface area of the glomerular
capillary network and a decline in eGFR.23 In addition, chronic
renal hypoperfusion related to atherosclerosis of the renal artery
reduces the glomerular capillary ultrafiltration coefficient and
good glycemic control group (P¼0.83) and poor glycemic control
are significantly higher compared with those of the normo- an
(P<0.001) and poor glycemic control group (P<0.001).efferent arteriolar blood flow and can also induce global
sclerosis, ultimately causing a progressive decrease in eGFR.24
Hemodynamic changes due to atherosclerotic renal disease as a
6 | www.md-journal.comchronic macrovascular complication might be associated with
isolated renal dysfunction without albuminuria in patients with
diabetes. In addition, macrovascular disease is frequently
accompanied by profound atherosclerosis in another area, such
as the cardiovascular or cerebrovascular system.21,22 A previous
study also demonstrated that patients with normoalbuminuric
type 2 diabetes with reduced eGFR presented with a pattern of
intrarenal vascular disease similar to those with micro- and
macroalbuminuria with renal impairment.9,25 A previous cross-
sectional study showed that patients with normoalbuminuric
diabetic CKD were more likely to have a history of CVD.26
up (P¼0.42). The renal outcomes in the macroalbuminuria group
icroalbuminuria groups in both good glycemic control groupPatients with normoalbuminuric advanced CKD also had a
higher incidence of macroangiopathies than patients with nor-
moalbuminuric stage 1 or 2 CKD in that study. The present
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 5. Demographic Characteristics of Subjects After Propensity Score Matching
NA (n¼ 145) MiA (n¼ 145) MA (n¼ 145) P
Age, y 61.16 8.94 64.17 9.27 64.17 9.25 0.99
DM duration, y 10.90 8.91 11.15 8.73 10.61 8.02 0.86
CVD history, n, % 53 (36.55%) 48 (33.10%) 53 (36.55%) 0.77
eGFR, mL/min/1.73m2 42.48 11.92 42.56 12.79 41.65 14.65 0.80
Data are expressed as mean standard deviation, or number of patients (percent).
CVD¼ cardiovascular disease, DM¼ diabetes mellitus, eGFR¼
MA¼macroalbuminuria, MiA¼microalbuminuria, NA¼ normoalbuminur
FIGURE 4. Kaplan–Meier plots for cardiovascular outcomes (A)
and renal outcomes (B) according to the amount of albuminuria
after propensity score matching. Cardiovascular outcomes are not
different among the three groups (P¼0.73). The renal outcomes in
the macroalbuminuria group are significantly higher compared with
those of the normo- and microalbuminuria groups (P<0.001).
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Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.study also revealed that the incidence of cardiovascular events
was similar between patients with normoalbuminuric diabetes
with renal dysfunction and patients with macroalbuminuric
diabetic CKD. Based on the results of this study and previous
studies, it appears that isolated renal dysfunction without overt
albuminuria reflects a macrovascular complication and is
associated with a relatively high incidence of CVD events in
patients with DKD. As expected, the present study showed that
an isolated decline in eGFR with insignificant albuminuria was
not associated with poor renal outcome, despite a similar
incidence of cardiovascular events among patients with
DKD. Meanwhile, there was a significant association between
the amount of albuminuria and the progression to a 50% decline
in eGFR or ESRD in this study population.
An increasing number of studies on diabetic patients with
renal insufficiency without albuminuria have published in
recent years.27,28 Several studies described clinical differences
between patients with macroalbuminuric and normoalbuminu-
ric diabetes10,26,29 but few studies have investigated the long-
term prognosis in this population. We classified patients into 3
groups (normoalbuminuria, microalbuminuria, and macroalbu-
minuria) based on the amount of albuminuria. In our study,
22.4% of patients with DKD were normoalbuminuric, which is
in line with previous findings.10,27 Patients in the macroalbu-
minuric group were much younger and had a longer duration of
diabetes compared with those in the normoalbuminuria and
microalbuminuria groups. Generally, albuminuria as a chronic
diabetic microvascular complication is a marker of glomerular
capillary damage and endothelial dysfunction, and is also
associated with a longer exposure to hyperglycemia in dia-
betes.30 Rigalleau et al31 also reported that normoalbuminuric
CKD patients had a lower duration of diabetes and a lower
incidence of diabetic retinopathy. In contrast, the prevalence of
hypertension was similar among patients with normo-, micro-,
and macroalbuminuria with a reduced eGFR. MacIsaac et al9
reported that patients with normoalbuminuria were significantly
older, which is consistent with our observation. Taken together,
the older age and shorter duration of diabetes in the normoal-
buminuria group suggest that isolated decreased eGFR in
patients with normoalbuminuria is associated with atherosclero-
tic vascular damage, such as nephrosclerosis or arterial hyali-
nosis, rather than chronic diabetic glomerular injury.32
Because of the distinct baseline characteristics of patients
in our study population, some important baseline covariates,
including history of CVD and age, were not distributed equally.
Patients in the normoalbuminuria group were significantly
older, had a shorter duration of diabetes, and had relatively
estimated glomerular filtration rate by CKD-EPI equation,
ia.preserved renal function, compared with those in the other
groups. Moreover, the development of cardiovascular compli-
cations might be influenced by a patient’s history of CVD and
www.md-journal.com | 7
other risk factors, such as age. Therefore, we used propensity
score matching and created among the 3 groups an identical
matched cohort at baseline. In this matched cohort, comparable
cardiovascular outcomes and distinguishable renal outcomes
were also observed among patients with normo-, micro-, and
macroalbuminuric diabetic CKD.
This study has several potential limitations that should be
noted. Because it was an observational retrospective study,
possible bias could not be excluded. In addition, because
subjects were screened at a tertiary hospital outpatient clinic
of a single center, certain characteristics of patients who pre-
sented to the hospital might have caused a selection bias (e.g., a
history of CVD and or more severe comorbid conditions).
Second, single measurements of the ACR were used for
analysis. Since the albumin excretion rate might be variable
in special circumstances (e.g., dehydration, exercise), the
absence of serial follow-up measurements was another limita-
tion of the present study. To compensate for this limitation, we
additionally performed an R square analysis from some of study
subjects, who are available the ACR values 3-month after study
enrollment. A total of 698 values of ACR at third month were
obtained. The adjusted R square of the initial ACR and the 3-
month ACRwas 0.94, which is significantly correlated. It seems
to be closely correlated with initial and third month ACR.
Nevertheless, we acknowledge this is limitation of our study.
Finally, we did not include medication history (e.g., angioten-
sin-converting enzyme inhibitors or angiotensin receptor block-
ers), and it is possible that the use of such medications affects
the amount of albuminuria. The use of statins or antiplatelet
agents might also affect cardiovascular outcomes. Therefore,
the lack of data regarding concomitant medication history is
another limitation of this study. Despite these limitations, we
conclude that, irrespective of the amount of albuminuria,
patients with diabetic CKD have a higher incidence of CVD
and isolated renal dysfunction without significant albuminuria,
and should be considered as being at high risk for CVD.
In conclusion, there are significant and substantial differ-
ences among diabetic patients with renal dysfunction according
to their level of albuminuria. However, the incidence of cardi-
ovascular events among normoalbuminuric, microalbuminuric,
and macroalbuminuric groups is comparable in patients with
diabetes and advanced renal insufficiency.
REFERENCES
1. de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the
prevalence of diabetic kidney disease in the United States. JAMA.
2011;305:2532–2539.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the
risks of death, cardiovascular events, and hospitalization. N Engl J
Med. 2004;351:1296–1305.
3. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a
risk factor for development of cardiovascular disease: a statement
from the American Heart Association Councils on Kidney in
Cardiovascular Disease, High Blood Pressure Research, Clinical
Cardiology, and Epidemiology and Prevention. Circulation.
2003;108:2154–2169.
4. Hovind P, Tarnow L, Rossing P, et al. Predictors for the develop-
ment of microalbuminuria and macroalbuminuria in patients with
type 1 diabetes: inception cohort study BMJ (Clinical Research Ed).
Lee et al2004;328:1105.
5. Adler AI, Stevens RJ, Manley SE, et al. Development and
progression of nephropathy in type 2 diabetes: the United Kingdom
8 | www.md-journal.comProspective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–
232.
6. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am
Soc Nephrol. 2007;2:581–590.
7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on
renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy. N Engl J Med. 2001;345:861–869.
8. Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal
dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.
Diabetes. 2006;55:1832–1839.
9. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, et al. Nonalbumi-
nuric renal insufficiency in type 2 diabetes. Diabetes Care.
2004;27:195–200.
10. Dwyer JP, Parving HH, Hunsicker LG, et al. Renal dysfunction in
the presence of normoalbuminuria in type 2 diabetes: results from
the DEMAND study. Cardiorenal Med. 2012;2:1–10.
11. Pan CY, Ho LT, Soegondo S, et al. Prevalence of albuminuria and
cardiovascular risk profile in a referred cohort of patients with type
2 diabetes: an Asian perspective. Diabetes Technol Ther.
2008;10:397–403.
12. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012
update Am J Kidney Dis. 2012;60:850–886.
13. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular
filtration rate from serum creatinine and cystatin C. N Engl J Med.
2012;367:20–29.
14. Bash LD, Selvin E, Steffes M, et al. Poor glycemic control in
diabetes and the risk of incident chronic kidney disease even in the
absence of albuminuria and retinopathy: Atherosclerosis Risk in
Communities (ARIC) Study. Arch Intern Med. 2008;168:2440–2447.
15. Austin PC. An introduction to propensity score methods for reducing
the effects of confounding in observational studies. Multivariate
Behav Res. 2011;46:399–424.
16. Brantsma AH, Bakker SJ, Hillege HL, et al. Cardiovascular and
renal outcome in subjects with K/DOQI stage 1-3 chronic kidney
disease: the importance of urinary albumin excretion. Nephrol Dial
Transplant. 2008;23:3851–3858.
17. Li JJ, Kwak SJ, Jung DS, et al. Podocyte biology in diabetic
nephropathy. Kidney Int Suppl. 2007:S36–S42.
18. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for
renoprotection in patients with type 2 diabetic nephropathy: lessons
from RENAAL. Kidney Int. 2004;65:2309–2320.
19. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and
kidney function independently predict cardiovascular and renal
outcomes in diabetes. J Am Soc Nephrol. 2009;20:1813–1821.
20. Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular
complications of diabetes. JAMA. 2004;292:2495–2499.
21. Booth GL, Kapral MK, Fung K, et al. Relation between age and
cardiovascular disease in men and women with diabetes compared
with non-diabetic people: a population-based retrospective cohort
study. Lancet (London, England). 2006;368:29–36.
22. Stehouwer CD, Smulders YM. Microalbuminuria and risk for
cardiovascular disease: analysis of potential mechanisms. J Am Soc
Nephrol. 2006;17:2106–2111.
23. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic
nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4:444–452.
24. Lopez-Novoa JM, Rodriguez-Pena AB, Ortiz A, et al. Etiopathology
of chronic tubular, glomerular and renovascular nephropathies:
clinical implications J Transl Med. 2011;9:13.
Medicine  Volume 95, Number 15, April 201625. MacIsaac RJ, Panagiotopoulos S, McNeil KJ, et al. Is nonalbumi-
nuric renal insufficiency in type 2 diabetes related to an increase in
intrarenal vascular disease? Diabetes Care. 2006;29:1560–1566.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
26. Ito H, Takeuchi Y, Ishida H, et al. High frequencies of diabetic
micro- and macroangiopathies in patients with type 2 diabetes
mellitus with decreased estimated glomerular filtration rate and
normoalbuminuria. Nephrol Dial Transplant. 2010;25:1161–1167.
27. Molitch ME, Steffes M, Sun W, et al. Development and progression
of renal insufficiency with and without albuminuria in adults with
type 1 diabetes in the diabetes control and complications trial and
the epidemiology of diabetes interventions and complications study.
Diabetes Care. 2010;33:1536–1543.
Medicine  Volume 95, Number 15, April 2016absence of albuminuria and retinopathy among adults with type 2
diabetes mellitus. JAMA. 2003;289:3273–3277.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.29. Perkins BA, Ficociello LH, Roshan B, et al. In patients with type
1 diabetes and new-onset microalbuminuria the development of
advanced chronic kidney disease may not require progression to
proteinuria. Kidney Int. 2010;77:57–64.
30. Currie G, Delles C. Proteinuria and its relation to cardiovascular
disease. Int J Nephrol Renovas Dis. 2013;7:13–24.
31. Rigalleau V, Lasseur C, Raffaitin C, et al. Normoalbuminuric renal-
insufficient diabetic patients: a lower-risk group. Diabetes Care.
2007;30:2034–2039.
Cardiovascular Events in Normoalbuminuric Diabetic Patients32. Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in28. Kramer HJ, Nguyen QD, Curhan G, et al. Renal insufficiency in theNIDDM patients with microalbuminuria. Diabetologia.
1996;39:1569–1576.
www.md-journal.com | 9
